PubMed Health⌕ Search

Biomedical subjects

F M Rytikov

Publications and source records attributed to F M Rytikov.

6 recordsLinked to original sources
PubMed1993

Cholesterol uptake in the human intestine. Hypo- and hyperresponsiveness.

Cholesterol uptake was studied at the small intestine biopsies taken from patients without intestinal malfunction. Three distinct groups of patients were described: those with low (146 +/- 19) nmol/mm2 per 2 h), medium (455 +/- 18 nmol/mm2 per 2 h) and high (833 +/- 24 nmol/mm2 per 2 h) rates of cholesterol uptake. Positive correlation between cholesterol uptake and intestinal cholesterol synthesis was observed in the last two groups.

Acetates↗
PubMed1989

[Detection of Campylobacter pylori in children with chronic gastritis].

Examinations of the gastric mucosa biopsy specimens from 38 children suffering from chronic gastritis have revealed Campylobacter bacteria in 21 (55.3%). Studies of the cultural, morphologic, and biochemical characteristics of the isolated strains have identified them as C. pylori.

Adolescent↗
PubMedDate not supplied

[Combined antibacterial and probiotic therapy of Helicobacter-associated diseases in children].

On the basis of microbiological monitoring and clinico-morphological criteria, the use of probiotics containing lacto- and bifidobacteria, simultaneously with "triple" antibacterial therapy (antibiotics of choice, metronidazole and bismuth salts), has been found to produce curative effect in the treatment of Helicobacter-associated gastroduodenal pathology in children. The influence of "triple" antibacterial therapy on the microecology of the gastrointestinal tract and the state of the immunobiological status of patients was studied. The combined scheme for correcting damaged microbiocenosis with probiotics in accordance with the concept of microecological adequacy is proposed. The scheme includes modern antibacterial therapy in combination with the probiotic preparations of lactobacteria. The prescription of bifidobacteria-containing probiotics is recommended at early stages from the beginning of etiotropic therapy. The effectiveness of the therapy may be dynamically evaluated, starting from week 5 after the end of the complex therapy, in EIA with the use of specific anti-Helicobacter antibodies.

Anti-Bacterial Agents↗